会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Heteroaromatic derivatives
    • 杂芳族衍生物
    • US06291467B1
    • 2001-09-18
    • US09646309
    • 2000-09-15
    • Atsuro NakazatoToshihito KumagaiShigeyuki ChakiKazuyuki TomisawaMasashi NagamineMakoto GotohMasanori Yoshida
    • Atsuro NakazatoToshihito KumagaiShigeyuki ChakiKazuyuki TomisawaMasashi NagamineMakoto GotohMasanori Yoshida
    • C07D41706
    • C07D231/12C07D401/06C07D417/06
    • An aromaheterocyclic derivative represented by the formula: wherein Z is a group represented by the following formula: wherein Ar1 is a phenyl group or a phenyl group substituted with a halogen atom or an alkyl group of 1 to 5 carbon atoms, R2 is an alkyl group of 1 to 5 carbon atoms, Y is a hydrogen atom, a mercapto group, an alkylthio group of 1 to 5 carbon atoms, an amino group or an amino group substituted with one or two alkyl groups having 1 to 5 carbon atoms, Ar2 is a phenyl group of one or two substituents selected from the group consisting of a halogen atom, an alkyl group of 1 to 5 carbon atoms, an alkoxy group of 1 to 5 carbon atoms, a hydroxyl group and a trifluoromethyl group, or a phenyl group, B1-B2 is CH—CO or C═C(R1) (wherein R1 is a hydrogen atom or an alkyl group of 1 to 5 carbon atoms), and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof, which is a dopamine D4 receptor antagonist compound having an antipsychotic action without causing extrapyramidal diseases.
    • 由下式表示的芳族杂环衍生物:其中Z为下式表示的基团:其中Ar1为苯基或被卤素原子或1〜5个碳原子的烷基取代的苯基,R2为烷基 1〜5个碳原子,Y为氢原子,巯基,1〜5个碳原子的烷硫基,氨基或被一个或两个碳原子数为1〜5的烷基取代的氨基,Ar2为 选自卤素原子,1〜5个碳原子的烷基,1〜5个碳原子的烷氧基,羟基和三氟甲基,或苯基中的一个或两个取代基的苯基 ,B1-B2为CH-CO或C = C(R1)(其中R1为氢原子或1〜5个碳原子的烷基),n为1〜4的整数,或其药学上可接受的盐 ,其是具有抗精神病作用而不引起外敷的多巴胺D4受体拮抗剂化合物 痉挛性疾病
    • 10. 发明授权
    • 4-Tetrahydropyridylpyrimidine derivatives
    • 4-四氢吡啶基嘧啶衍生物
    • US06187781B1
    • 2001-02-13
    • US09381462
    • 1999-09-21
    • Atsuro NakazatoToshihito KumagaiTaketoshi OkuboIzumi AibeHideo TanakaShigeyuki ChakiShigeru OkuyamaKazuyuki Tomisawa
    • Atsuro NakazatoToshihito KumagaiTaketoshi OkuboIzumi AibeHideo TanakaShigeyuki ChakiShigeru OkuyamaKazuyuki Tomisawa
    • C07D40144
    • C07D401/04C07D405/14C07D409/14
    • A 4-tetrahydropyridylpyrimidine compound represented by formula (I): wherein Ar represents a phenyl group substituted with 1 to 3 substituents selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, and a trifluoromethyl group, a phenyl group, a thienyl group or a furanyl group; R1 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms; R2 represents an alkyl group having 1 to 5 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms, an alkenyl group having 2 to 5 carbon atoms or an alkynyl group having 2 to 5 carbon atoms; and X1, X2, and X3, which may be the same or different, each represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof. The 4-Tetrahydropyridylpyrimidine compound finds utility in the treatment of diseases in which CRF is implicated.
    • 由式(I)表示的4-四氢吡啶基嘧啶化合物:其中Ar表示被1至3个选自卤素原子,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基的取代基取代的苯基, 和三氟甲基,苯基,噻吩基或呋喃基; R1表示氢原子,碳原子数1〜5的烷基,氨基或被1〜2个碳原子数1〜2的烷基取代的氨基。 R2表示碳原子数1〜5的烷基,碳原子数4〜7的环烷基烷基,碳原子数2〜5的烯基或碳原子数2〜5的炔基。 X 1,X 2和X 3可以相同或不同,分别表示氢原子,卤素原子,碳原子数1〜5的烷基,碳原子数1〜5的烷氧基,烷硫基, 1至5个碳原子的氨基或被1或2个具有1至5个碳原子的烷基取代的氨基,或其药学上可接受的盐。 4-四氢吡啶基嘧啶化合物可用于治疗涉及CRF的疾病。